PZ0242
PF-06658607
≥98% (HPLC)
别名:
Probe 4, 依鲁替尼, （R）-1-（3-（4-氨基-3-（4-（3-乙炔基苯氧基）苯基）-1H-吡唑并[3,4-d]嘧啶-1-基）哌啶-1-基）丙-2-烯-1-酮
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
room temp
Quality Level
Application
PF-06658607 已用于评价共价激酶抑制剂的全蛋白选择性。
Biochem/physiol Actions
PF-06658607 是一种烷基化不可逆的 Brutons 酪氨酸激酶（BTK）抑制剂。
PF-06658607 是一种烷基化不可逆的 Brutons 酪氨酸激酶（BTK）抑制剂，可与 ATP 结合袋中的活性位点半胱氨酸残基共价反应。PF-06658607 已被用作蛋白质组分析的探针，以鉴定脱靶结合底物。炔烃部分允许通过铜催化的点击化学方法添加基于叠氮化物的检测探针。
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Bryan R Lanning et al.
Nature chemical biology, 10(9), 760-767 (2014-07-21)
Kinases are principal components of signal transduction pathways and the focus of intense basic and drug discovery research. Irreversible inhibitors that covalently modify non-catalytic cysteines in kinase active sites have emerged as valuable probes and approved drugs. Many protein classes
相关内容
The Cravatt group develops innovative technologies to understand enzyme roles in disease, focusing on activity-based protein profiling.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持